Abstract
Population based studies demonstrate strong familial recurrence of cardiac malformations particularly for individuals affected with a specific class of CHD, left-ventricular outflow tract (LVOT) obstruction. Recently we linked 99 lead variants across 71 loci to diameter of the ascending aorta derived from MRI measurements across multiple ethnicities in the UK Biobank. Using these data we created a polygenic risk score capturing ascending aortic diameter (PRSAoD) Among 2,594 individuals with CHD; a decrease by one standard deviation in PRSAoD was associated with an increased risk of congenital LVOT (OR=1.14[1.03-1.26], p=0.014) but not with other subtypes of CHD. Using Mendelian Randomization we observed strong evidence of a causal effect where inheritance of a smaller diameter of the ascending aorta corresponded to an increase in risk for congenital LVOT (p_IVW = 0.008). Our data may suggest that genetic determinants of a smaller ascending aorta act during early development to disturb blood flow through left-sided structures to increasing the risk of LVOT CHD, which is consistent with experimental evidence and the “no flow, no grow” paradigm in the formation of the left ventricular outflow tract.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funded by the National Institutes of Health (NIH) (R00HL130523 to J.R.P.) and the Stanford Department of Pediatrics (J.R.P.). Other than the above reported grants, no authors or their institutions at any time received payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, or statistical analysis).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the research is conducted on de-identified genetic data obtained from consented individuals outside the institution in the UK which has been exempted from human subjects research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data from the ascending aorta is available online while data on individuals with congenital heart disease is available upon request from Dr. Heather Cordell (heather.cordell@newcastle.ac.uk).